Verenium Corporation (VRNM)
-NasdaqGM 2.20 
0.08(3.77%) May 17, 3:58PM EDT
| Prev Close: | 2.12 |
|---|
| Open: | 2.13 |
|---|
| Bid: | 2.05 x 500 |
|---|
| Ask: | 2.46 x 100 |
|---|
| 1y Target Est: | 2.60 |
|---|
| Beta: | 0.8 |
|---|
| Next Earnings Date: | 5-Aug-13 |
|---|
| Day's Range: | 2.11 - 2.24 |
|---|
| 52wk Range: | 2.05 - 4.69 |
|---|
| Volume: | 19,424 |
|---|
| Avg Vol (3m): | 16,140 |
|---|
| Market Cap: | 28.12M |
|---|
| P/E (ttm): | N/A |
|---|
| EPS (ttm): | -1.38 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- 4 Obscure Healthcare Stocks To Watch In 2013at Seeking Alpha(Mon, May 13)
- VERENIUM CORP Files SEC form 10-Q, Quarterly ReportEDGAR Online(Fri, May 10)
- Verenium's CEO Discusses Q1 2013 Results - Earnings Call Transcriptat Seeking Alpha(Thu, May 9)
- Verenium Reports Financial Results For The First Quarter Ended March 31, 2013PR Newswire(Thu, May 9)
- VERENIUM CORP Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and ExhibitsEDGAR Online(Thu, May 9)
- Q1 2013 Verenium Corporation Earnings Release - After Market CloseCCBN(Thu, May 9)
- Verenium Corporation to Announce First Quarter 2013 Financial ResultsPR Newswire(Thu, May 2)
- VERENIUM CORP FinancialsEDGAR Online Financials(Fri, Apr 5)
- VERENIUM CORP Files SEC form 10-K, Annual ReportEDGAR Online(Mon, Apr 1)
- Verenium's CEO Discusses Q4 2012 Results - Earnings Call Transcriptat Seeking Alpha(Wed, Mar 27)
- Verenium Reports Financial Results For The Fourth Quarter And Year Ended December 31, 2012PR Newswire(Wed, Mar 27)
- VERENIUM CORP Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and ExhibitsEDGAR Online(Wed, Mar 27)
- Q4 2012 Verenium Corporation Earnings Release - After Market CloseCCBN(Wed, Mar 27)
- Verenium Corporation To Announce Fourth Quarter And Year End 2012 Financial ResultsPR Newswire(Mon, Mar 18)
- VERENIUM CORP Files SEC form 8-K, Results of Operations and Financial Condition, Non-Reliance on Previous Financials,EDGAR Online(Thu, Mar 14)
Key Statistics
| Forward P/E (1 yr): | N/A |
|---|
| P/S (ttm): | 0.50 |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Dec-13)
: | -1.55 |
|---|
| Quarterly EPS Est
(Jun-13)
: | -0.32 |
|---|
| Mean Recommendation*: | 3.0 |
|---|
| PEG Ratio (5 yr expected): | -0.03 |
|---|
Business Summary
Verenium Corporation, an industrial biotechnology company, engages in the development and commercialization of enzymes for industrial processes in North America, Europe, South America, and Asia.
View More